Vivus shares slide on downgrade; FDA puts off decision on AMAG's app for new Feraheme use;

@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma

@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce

> The FDA extended its review of AMAG Pharma's application for broader use of its anemia therapy, Feraheme, for three months. Report

> Vivus ($VVUS) shares slid after a Piper Jaffray analyst lowered his price target and cut his rating on the stock, after disappointing prescription numbers on its weight-loss drug Qsymia. Report

> The global vaccine alliance is rolling out a low-cost human papillomavirus (HPV) vaccine program, using discounted shots from Merck ($MRK) and GlaxoSmithKline ($GSK), in Laos this week. Report

> Most common tumors are driven by only a few gene mutations, according to a new study, which may help identify new uses for approved cancer drugs that target specific genetic changes. Report

> The FDA pulled an antibiotic from B. Braun Medical, cefepime, after vials were found to contain bits of metal, cotton and hair. Report | More from FiercePharmaManufacturing

Medical Device News

@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev

@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce

@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future delivery. Article | Follow @MichaelGFierce

> Roche will close 454 Life Sciences and stop making its gene sequencing tech. Item

> Wright buying implant outfit for $80M with eye on Europe. News

> Quest blames outside factors for lowering already diminished 2013 expectations. More

> Device tax repeal fight fails again as government funding bill avoids the issue. Article

Biotech News

@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech

@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce

@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce

@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce

> Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff. Article

> Roche: Forget mega-mergers, focus on a new round of blockbuster bolt-ons. Story

> Amarin shares shrivel after FDA experts spurn Vascepa. Item

> AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu. Report

Pharma Manufacturing News

@EricPFierce: Another gut check for Amarin and its fish oil drug : panel votes against wider use. News | Follow @EricPFierce

> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report

> Federal case over drug shortage comes to an end. Story

> Teva reconsiders production cuts in Israel. Item

> B. Braun recalls product after organic particulate found. More

> Genzyme expanding U.S. plant opened last year. Article

Vaccines News

> Cost of rabies vaccine limiting use in Africa. Report

> Merck, Sanofi report on first vaccine in European pilot project. More

> IOM releases modeling software for vaccine prioritization. Item

> Novartis cuts jobs in California as eastward shift continues. More

> India to expand use of pentavalent vaccine after safety thumbs-up. Article

> U.K. court orders sisters to receive MMR vaccine. Story

And Finally... Working against your natural body clock causes "social jet lag," which increases the risk of a variety of health problems, including obesity, a researcher says. Report (sub. req.)

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.